Evidence map›Paper›PMID 29573529›Full record

Trial reportDiabetes, obesity & metabolism2018

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05565976 (Dapagliflozin Effect in Cognitive Impairment in Stroke Trial), which is not on this map. Cited by 143 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 9 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05565976 phase2 / phase3unknown statusstarted 2020, after this paper: background citation

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Ran2020Enrolled270Registered outcomes3Posted comparisons0ConditionsDementia, Vascular, Metabolic Syndrome, Mild Cognitive Impairment, Stroke, IschemicArmsAntidiabetic, Dapagliflozin 10mg Tab, Platelet Antiaggregant, Statins (Cardiovascular Agents)
PMID 33282811PMID 20204386PMID 23040716PMID 28095900PMID 28950419PMID 29016744PMID 29371333PMID 29446769PMID 31236801PMID 31248555PMID 31535829PMID 32115470other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 9 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Claire C J DekkersDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-5565-7240
Sergei PetrykivDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Gozewijn D LavermanDepartment of Nephrology, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands.
David Z CherneyDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Canada.
Ron T GansevoortDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-3126-3730
University Medical Center Groningen · NLUniversity of Toronto · CAZiekenhuis Groep Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms by which SGLT-2 inhibitors lower albuminuria are incompletely understood. We assessed in a post-hoc analysis of a cross-over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM-1, NGAL and LFABP) and inflammatory markers (urinary MCP-1 and IL-6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%-54.8%) and eGFR by 5.1 (2.0-8.1) mL/min/1.73m

Indexed as

Acute Kidney InjuryAdultAlbuminuriaAnti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsBiomarkersCross-Over StudiesDiabetes Mellitus, Type 2Diabetic NephropathiesDouble-Blind MethodGlomerular Filtration RateGlucosidesHepatitis A Virus Cellular Receptor 1HumansInflammation MediatorsInterleukin-6Anti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsBiomarkersdapagliflozinGlucosidesHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1IL6 protein, humanInflammation MediatorsInterleukin-6Sodium-Glucose Transporter 2 Inhibitorsacute kidney injurydapagliflozinKIM-1MCP-1SGLT-2type 2 diabetes

Identifiers

PMID29573529
PMCPMC6055757
OpenAlexW2791162071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.